[The cytotoxicity of Her-2 pulsed DCIKS against breast cancer cells].
To study DCIK co-culture system with Her-2 as the pulsing antigen peptide of DC and the cytotoxicity of DCIKs against the breast cancer cells, CIK and DC were first induced and isolated from human peripheral blood. CIK and DC pulsed with antigen Her-2 peptide were then co-cultured to prepare CIK-DC co-culture system (DCIK-P). Using DCIK-P as effect cells and breast tumor cells (MDA-MB-231, SK-BR-3, MCF-7) as target cells,the antigen-specicfic cytotox-icity of DCIK-P was analysed by cell viability and cytotoxicity assay. The killer activity of DCIKs against the MDA-MB-231, SK-BR-3 and MCF-7 is 50.38% +/- 3.25%, 52.19% +/- 3.25% and 47.09% +/- 2.41% respectively. The killer activity of DCIK-Ps against the MDA-MB-231, SK-BR-3 and MCF-7 is 76.30% +/- 1.74% (P < 0.001), 55.70% +/- 3.05% (P = 0.014) and 47.67% +/- 2.40% (P = 0.697) respectively. The killer activity of DCIK-P cells was greatly enhanced against Her-2(+) breast tumor cell strains. The present results can provide tumor immunological data and experimental techniques for the development of breast tumor treatment.
Ying
Xue Xiang
XX
Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China.
Zou
Qiang
Q
Xu
Yong Hua
YH
Wang
En Zhong
EZ
Wang
Hong Ying
HY
Hu
Yi Hong
YH
Ni
Quan Xing
QX
D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000276:immunology; D018920:Coculture Techniques; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D003713:Dendritic Cells / Q000166:cytology / Q000276:immunology*; D005260:Female; D006801:Humans; D015979:Killer Cells, Lymphokine-Activated / Q000166:cytology / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics / Q000276:immunology* / Q000378:metabolism
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human